首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Future Oncology

Future Oncology杂志,由Future Medicine Ltd.出版,于2005年创刊,Monthly,出版语言English,ISSN:1479-6694,E-ISSN:1744-8301。

投稿咨询
Future Oncology
Future Oncology
Future Oncology
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
4区
影响因子
3.1
CiteScore
4.9
期刊收录
SCI、SCIE

Future Oncology(中文译名:《未来肿瘤学》),ISSN:1479-6694,EISSN:1744-8301,是Future Medicine Ltd.出版的国际性学术期刊,创刊于2005年,以Monthly形式稳定发行,2026年总发文量约290篇。该刊采用非OA开放访问,学科归属为ONCOLOGY。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达3.1,2025年期刊CiteScore为4.9,2025年期刊自引率约0%,在中科院期刊分区体系中位列医学大类4区,在所属学科领域具备高学术影响力与国际认可度。Future Oncology长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期偏慢,4-8周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、Italy、England、GERMANY (FED REP GER)、France、Spain等为核心发文国家与地区;UNIVERSITY OF TEXAS SYSTEMUNICANCER、PFIZER、HARVARD UNIVERSITY、SHANDONG FIRST MEDICAL UNIVERSITY & SHANDONG ACADEMY OF MEDICAL SCIENCES、SUN YAT SEN UNIVERSITY、UNIVERSITY OF LONDON等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学
4区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学
4区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学
4区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 165 / 333

50.6

学科:ONCOLOGY SCIE Q3 185 / 333

44.59

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q3 181 / 328

45

学科:ONCOLOGY SCIE Q3 191 / 328

41.92


中国学者近期发文

1
Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey stud

Author:Wu, Di; Murali, Bhavna; Clark, Otavio; Luan, Luan; Hlavacek, Patrick; Chaudhary, Mohammed Ashraf; Aydin, Didem; DiBonaventura, Marco

Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 10, pp. 1213-1219. DOI: 10.1080/14796694.2026.2656394

2
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCL

Author:Peters, Solange; Hochmair, Maximilian; Arbour, Kathryn C.; Rodriguez, Luis Paz-Ares; Reck, Martin; Leal, Ticiana; R. Lindsay, Colin; Shun, Lu; William, William Nassib; Spira, Alexander I.; Sabari, Joshua K.; Henning Grønberg, Bjørn; Nishio, Makoto; Burns, Timothy F.; Girard, Nicolas; Capuzzo, Frederico; Merced, Alyson; Fasnacht, Nicolas; Visseren-Grul, Carla; Negrao, Marcelo V

Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 9, pp. 1073-1082. DOI: 10.1080/14796694.2026.2651961

3
Comparison of concurrent chemoradiotherapy followed by immunotherapy and induction chemoimmunotherapy followed by radiotherapy in unresectable stage III NSCLC: a retrospective cohort stud

Author:Xu, Qinhao; Qi, Yana; Zhai, Xiaoyang; Chen, Feihu; Guo, Yingfan; Zhu, Hui

Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 7, pp. 819-829. DOI: 10.1080/14796694.2026.2637732

4
Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial design

Author:Yu, Evan Y.; Gratzke, Christian; Burotto, Mauricio; Zhang, Alison Y.; Levesque, Eric; Ortega, Francisco; Peer, Avivit; Vile, Donald; Chen, Zheng Hong; Song, Yue; Schloss, Charles; Todoric, Jelena; Garratt, Chris; Poehlein, Christian; Antonarakis, Emmanuel S.; Fizazi, Karim

Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 7, pp. 765-772. DOI: 10.1080/14796694.2025.2595914

5
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumor

Author:Schram, Alison M.; Park, John J.; Italiano, Antoine; Kitano, Shigehisa; Guo, Ye; Li, Jin; Bedard, Philippe L.; van Marcke, Cedric; Ko, Ryo; Lunger, Lukas; Klotz, Daniel M.; Hussain, Jo; Maier, Daniela; Erzen, Damijan; Planchard, David; Prenen, Hans; Clay, Timothy D.; Park, Joon O.; Kim, Hyung-Don; Hernando-Calvo, Alberto; Maruki, Yuta; Ponz-Sarvise, Mariano; Dumbrava, Ecaterina

Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 7, pp. 795-803. DOI: 10.1080/14796694.2026.2637740

6
Precision palliative care in advanced/recurrent esophageal cancer patients treated with anti-PD-1/PD-L1 immunotherapy (ESO-Shanghai 25): a randomized, phase III Tria

Author:Hao, Shengnan; Wang, Xiaomin; Ding, Huiping; Chen, Yun; Liu, Qi; Zhang, Junhua; Fan, Xingwen; Wu, Zhenhua; Lin, Ying; Xu, Xiaofang; Mao, Guangmin; Ai, Dashan; Deng, Jiaying; Zhu, Hongcheng; Ye, Jinjun; Mo, Miao; Hu, Zhihuang; Wang, Huijie; Cheng, Wenwu; Feng, Wei; Ling, Yiqun; Xu, Yufen; Du, Shisuo; Wang, Jialei; Zhao, Kuaile

Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 7, pp. 773-780. DOI: 10.1080/14796694.2026.2637738

7
Nivolumab plus chemotherapy in Asian people with advanced or recurrent stomach or gastroesophageal junction cancer (ATTRACTION-4 study): a plain language summar

Author:Chen, Li-Tzong; Kang, Yoon-Koo; Ryu, Min-Hee; Oh, Do-Youn; Oh, Sang Cheul; Rha, Sun Young; Lee, Keun-Wook; Omori, Takeshi; Shitara, Kohei; Sakuramoto, Shinichi; Chung, Ik-Joo; Yamaguchi, Kensei; Kato, Ken; Sym, Sun Jin; Kadowaki, Shigenori; Tsuji, Kunihiro; Chen, Jen-Shi; Bai, Li-Yuan; Oh, Sung-Yong; Choda, Yasuhiro; Yasui, Hisateru; Takeuchi, Kentaro; Hirashima, Yoshinori; Hagihara, Shunsuke; Boku, Narikazu

Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 6, pp. 625-642. DOI: 10.1080/14796694.2026.2622806

8
Efficacy and safety of anti-CLDN18.2 therapies in advanced or metastatic gastric, gastro-oesophageal junction, and oesophageal carcinomas with CLDN18.2 positivity: a systematic review and meta-analysi

Author:Zhang, Yaping; Kao, Shangbin; Li, Dian; Yan, Canlong; Huang, Biao; Fang, Hongming

Journal: FUTURE ONCOLOGY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14796694.2026.2659354

9
Significance of the HALP score in patients with primary liver cancer undergoing hepatectomy: a meta-analysi

Author:Zhang, Min; Xu, Kailin; Ye, Jufeng

Journal: FUTURE ONCOLOGY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14796694.2026.2646142

10
Concurrent immunotherapy is associated with increased radiation necrosis risk in lung cancer patients with brain metastases treated with stereotactic radiosurger

Author:Du, Guochang; Li, Wanjing; Li, Ji; Yu, Jinming; Zhu, Hui

Journal: FUTURE ONCOLOGY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14796694.2026.2642933


在线咨询

Future Oncology

国际简称:FUTURE ONCOL参考译名:未来肿瘤学

年发文量:290 CiteScore:4.9 是否预警:否 Gold OA文章占比:23.77% 研究类文章占比:79.31%

杂志社联系方式:FUTURE MEDICINE LTD, UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB

Future Oncology